Summary
This study was an open efficacy and safety study of teicoplanin in hospitalized patients with gram-positive infections. 26 patients entered the study. Teicoplanin was administered by intravenous bolus injection at a dose of 200 mg or 400 mg every 24 h, and in all cases an initial loading dose of 400 mg was given. The mean duration of treatment was 9.4 days (range four to 20 days). The infections included 18 skin/soft tissue, four lower respiratory tract, two urinary tract and two joint/bone. Clinical cure and improvement occurred in 20 of the 26 patients. Only two adverse events (moderate diarrhoea and mild pain at injection site) related to teicoplanin occurred in one patient. It was concluded that teicoplanin was effective and well tolerated in the treatment of gram-positive infections.
Zusammenfassung
In einer offenen Studie wurde die klinische Wirksamkeit und Verträglichkeit von Teicoplanin bei 26 Patienten mit grampositiven Infektionen geprüft. Teicoplanin wurde mittels i.v. Bolusinjektion in der Dosierung von 200 mg oder 400 mg alle 24 Stunden verabreicht. In allen Fällen wurde eine Initialdosis von 400 mg gegeben. Die durchschnittliche Behandlungsdauer betrug 9,4 Tage (4–20 Tage). Folgende Infektionen wurden behandelt: 18 Haut/Weichteile, vier untere Atenwege, zwei Harnwege und zwei Knochen/Gelenke. Eine klinische Heilungs- und Besserungsrate wurde bei 20 der 26 Patienten erzielt. Nur zwei unerwünschte Arzneimittelwirkungen (mäßige Diarrhoe und leichter Schmerz an der Injektionsstelle) wurden bei einem Patienten beobachtet. Die Ergebnisse lassen darauf schließen, daß Teicoplanin in der Behandlung von grampositiven Infektionen wirksam und gut verträglich ist.
Similar content being viewed by others
References
Mak, D. G. Nosocomial bacteremia. An epidemiologic overview. Am. J. Med. 70 (1981) 719.
Wenzel, R. P. The emergence of methicillin — resistantStaphylococcus aureus. Ann. Intern. Med. 97 (1982) 440–442.
Whiteside, M., Moove, J., Katzan, R. An investigation of enterococcal bacteraemia. Am. J. Inf. Control. 11 (1983) 125.
Bauernfeind, A., Petermüller, C.: In vitro activity of teichomycin A 2 in comparison with penicillin and vancomycin against gram-positive cocci. Eur. J. Clin. Microbiol. (1982) 278–281.
Fainstein, V., LeBlanc, B., Bodey, G. P. Comparativein vitro study of teichomycin A 2. Antimicrob. Agents Chemother. 23 (1983) 497–499.
Breyer, S., Georgopoulos, A. Graninger, W. In vitro evaluation of teicoplanin and other antimicrobials against streptococci group D bacteria. Drugs Exp. Clin. Res. 13 (1987) 479–481.
McNulty, C. A. M., Garden, G. M. F., Wise, R., Andrews, J. M. The pharmacokinetics and tissue penetration of teicoplanin. Antimicrob. Chemother. 16 (1985) 743–749.
Pallanza, R., Berti, M., Goldstein, B. P., Mapelli, E., Randisi, E., Scotti, R. Teichomycin:In vitro andin vivo evaluation in comparison with other antibiotics. Antimicrob. Chemother. 11 (1983) 419–425.
Pallanza, R., Scotti, R., Arioli, V. Bactericidal activity of teicoplanin in anin-vitro two-compartment kinetic model. J. Antimicrob. Chemother. 21 Suppl. A (1988) 15–21.
Traina, G. L., Bonati, M. Pharmacokinetics of teicoplanin in man after intravenous administration. J. Pharmacokinet. Biopharm. 12 (1984) 119–128.
Verbist, L., Tjandramaga, B., Hendrickx, B., Van Hecken, A., Van Melle, P., Verbesselt, R., Verhaegen. J., DeSchepper, P. J. In vitro activity and human pharmacokinetics of teicoplanin. Antimicrob. Agents Chemother. 26 (1984) 881–886.
Stille, W., Sietzen, W., Dieterich, H. A., Fell, J. J. Clinical efficacy and safety of teicoplanin. J. Antimicrob. Chemother. 21 Suppl. A (1988) 69–79.
Cavenaghi, L. A., Giani, E., Corti, A., Cassani, G.: Determinations of teicoplanin in tissues and biological fluids. First Biennial Conference on Chemotherapy of Infectious Diseases and Malignancies (BICON), Munich 1987, Abstract No. 122.
Deutsches Institut für Normung e. V.: Methoden zur Empfindlichkeitsprüfung von bakteriellen Krankheitserregern (außer Mykobakterien) gegen Chemotherapeutika. Agar Diffusionstest. In DIN 58940, Teil 3 (1981), Beuth Verlag, Berlin, F. R. G.
Sanders, C. V., Hanna, B. J., Lewis, A. C. Metronidazole in the treatment of anaerobic infections. Am. Rev. Respir. Dis. 120 (1979) 337–343.
Nigam, P., Kappoor, K. K., Guptar, R. K., Guptar, A. K., Goyal, B. M. Metronidazole in pulmonary anaerobic infection. J. Assoc. Physicians India 31 (1983) 779–781.
Perlino, C. A. Metronidazole vs. clindamycin treatment of anaerobic pulmonary infection. Arch. Intern. Med. 141 (1981) 1424–1427.
Eykyn, S. J. The therapeutic use of metronidazole in anaerobic infection: Six years experience in a London hospital. Surgery 93 (1983) 209–214.
Author information
Authors and Affiliations
Additional information
Supported by Merrell Dow Pharma GmbH, Rüsselsheim, FR Germany.
Rights and permissions
About this article
Cite this article
Kempf, P., Pompetzki, H., Oppermann, A. et al. Clinical efficacy and safety of teicoplanin in the treatment of gram-positive infections. Infection 17, 177–181 (1989). https://doi.org/10.1007/BF01644026
Issue Date:
DOI: https://doi.org/10.1007/BF01644026